

Dr. Kevin Wang has 25 years of unique combination of experience in drug discovery and development in pharmaceutical industry, basic and clinical research in academia, and founding and managing a biotechnology/diagnostic company. Upon obtaining his Ph.D. in Pharmaceutical Sciences with Distinction from the University of British Columbia (Vancouver) in 1989 and finishing a postdoctoral fellowship (Pathology) at Wayne State University (Detroit) in 1991, Dr. Wang joined Parke-Davis Pharmaceutical Research (Ann Arbor) in 1991, and joined Pfizer Inc. following its' merger with Parke-Davis (2000).

He rose through the rank to become Group Leader of CNS Therapeutics and CoChair the CNS New Targets Team. One of the projects that he led had resulted in a Lead Compound candidate. Meanwhile, he also co-chaired the Far East Scientific Opportunity Team. In 2002, he transitioned to academia and became Associate Professor of Psychiatry at the University of Florida (Gainesville, FL) and Associate Director of the Center for Traumatic Brain Injury Studies. In 2002, he co-founded Banyan Biomarkers Inc. (Alachua, FL).

In 2007, he transitioned to Banyan as full-time Chief Scientific Officer and Director of its Center of Innovative Research, where he oversaw a team of more than 30 PhD, MS and BSc scientists and staff. Dr. Wang has contributed significantly to the discovery and product development of two acute brain injury protein biomarkers (UCH-L1 and GFAP) and their diagnostic utility characterization in several animal and human brain injury studies. This biomarker tandem is now in pivotal study for FDA approval as a first-in-class in vitro diagnostic (IVD) test for mild/moderate traumatic brain injury (ALERT Trial).

In 2011, he rejoined the University of Florida McKnight Brain Institute as Director of the Program for Neurotrauma, Neuroproteomics & Biomarkers Research / Associate Professor of Psychiatry, Neuroscience and Physiological Science, where he continues basic and translational research in neurotherapeutics and neurodiagnostics. He is also Chair Professor of Neurosurgery at the Taipei Medical University. Dr. Wang is internationally recognized for his original contributions to the fields of CNS disorders-linked drug targets, neuroproteomics and disease biomarker discovery.

Dr. Wang published more than 220 peer-reviewed papers, reviews and book chapters and co-authored 12 US and international patents. He co-edited four books on the topics that range from proteases, neuroproteomics to biomarkers for CNS disorders. He is Associate Editor of two journals - Translational Proteomics and Frontiers in Neurotrauma. He also serves on five international journals' Editorial Board. Dr. Wang was Past President and is current Council Member of the National Neurotrauma Society (USA).

His research interests include Neuro-Proteomics, Systems Biology, brain and spinal cord Injury, chronic traumatic encephalopathy (CTE), Tauopathy, Neurodegeneration, substance abuse research, Posttranslational modification (Protease / Protein Kinase) research, Biomarkers, Diagnostics and Therapeutic development.